Revvity, Inc. · NYSE:RVTY
Revvity — Q3 2025 Earnings Presentation
9 slides from Revvity's earnings presentation, Oct 27, 2025
Slide 1: Third Quarter 2025 Earnings
Third Quarter 2025 Earnings October 27, 2025
Slide 2: Safe Harbor
Safe Harbor This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial
Slide 3: Key Takeaways
Key Takeaways Innovation Market Performance New screening program for Stable Pharma & Academic Software & Newborn driving Type 1 Diabetes market demand solid overall growth New AI driven offerings for Strong Diagnostic trends EPS above expectations with in vivo & base editing outside of China strong
Slide 4: 3Q25 Revenue Highlights
3Q25 Revenue Highlights Segments Geographic Product Mix Diagnostics Life Sciences AMERICAS APAC EU Recurring Non-recurring -LSD -MSD +LSD $0.7 B Flat +LSD $0.7 B +LSD $0.7 B +MSD Reconciliations to the most directly comparable GAAP measure for the non-GAAP terms presented above are provided on our w
Slide 5: 3Q25 Financial Results
3Q25 Financial Results REVENUE ADJUSTED OP MARGIN ADJUSTED EPS FREE CASH FLOW $699M 26.1% $1.18 $120M +2% y/y -220bps y/y -8% y/y $354M YTD Organic: Adj. Gross Margin: Adj. Tax Rate: YTD FCF % Adj. NI: +1% | M&A: 0% | FX: +1% 58.7% | -300bps y/y 15.0% 89% Adj. Net Interest & Other: $22M Reconciliati
Slide 6: Life Sciences
Life Sciences LIFE SCIENCE SOLUTIONS SOFTWARE REVENUE AJUSTED OP MARGINS +DD 0% Organic Growth 29.5% Reported: 1% | M&A: 0% | FX: +1% -310bps y/y $343 M • +LSD growth from Pharma/Biotech, -LSD decline from 3Q25 revenue Academic/Gov’t -LSD • -LSD decline in Life Science Solutions consistent with YTD
Slide 7: Diagnostics
Diagnostics IMMUNODIAGNOSTICS REPRODUCTIVE REVENUE AJUSTED OP MARGINS HEALTH 2% Organic Growth 25.1% Reported: 3% | M&A: 0% | FX: +2% -210 bps y/y +MSD $356 M • -LSD ImmunoDX globally; +HSD growth ex China, -DD in China -LSD 3Q25 revenue • +MSD Reproductive Health driven by strength in newborn • Mar
Slide 8: 2025 Financial Guidance
2025 Financial Guidance REVENUE $2.83B - $2.88B Reported: 3% to 5% Organic: 2% to 4% FX: 1%, M&A: 0% ADJUSTED OP. MARGIN 27.1-27.3% ADJUSTED EPS $4.90 - $5.00 Adj. Net interest expense, other: ~$83M Adjusted tax rate: ~17% Average diluted share count: ~117M 8
Slide 9: Revvity.com
Revvity.com